Investigating how the A20 protein affects immune responses to tumors
Official title: A20 and Tumor Immune Responses
Funded at University of California, San Francisco · NIH-10990973 · Data updated 2026-11-12
This study is looking at how a protein called A20 helps control the immune system's response to solid tumors, with the hope that understanding this could lead to better cancer treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $552,874 |
| NIH project number | 1R01CA288237-01A1 |
| Project ID | NIH-10990973 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who may benefit from enhanced immune responses.
✕Less likely to help
Patients with non-solid tumors or those not expressing the A20 protein may not receive benefit from this research.
What this research studies
This research focuses on understanding the role of the A20 protein in regulating immune responses against solid tumors. By examining the cellular and molecular pathways influenced by A20, the study aims to uncover how this protein affects both pro-inflammatory signals and cell death in the tumor microenvironment. The approach includes advanced techniques like ATAC sequencing to analyze chromatin accessibility and identify specific biochemical motifs that may inhibit anti-tumor immunity. Patients may benefit from insights that could lead to improved cancer treatments targeting immune regulation.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing anti-tumor immunity in cancer patients.
How similar studies have gone: Previous research has shown promising results in targeting immune regulation for cancer treatment, suggesting potential success for this approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Ma, Averil I — University of California, San Francisco
- Study coordinator: Ma, Averil I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.